The identification and characterization of a STAT5 gene signature in hematologic malignancies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The Janus kinase-Signal transducer and activator of transcription (JAK-STAT) pathway is crucial for cellular signaling and is frequently dysregulated in human cancers.
• Identifying patients with activated JAK-STAT signaling is essential for targeted therapy with JAK inhibitors.

Purpose of the Study:

• To develop and validate a gene signature assay for detecting overactive JAK-STAT signaling.
• To correlate STAT5 activation with a specific set of STAT5 target genes in hematologic malignancies.

Main Methods:

• Utilized the Cancer Cell Line Encyclopedia and gene-expression data to identify STAT5 target genes.
• Correlated STAT5 activation status (pSTAT5) with the expression of four identified genes (PIM1, CISH, SOCS2, ID1) in 40 hematologic tumor cell lines.
• Assessed the effect of ruxolitinib treatment on gene signature expression and pSTAT5 levels in cell line models.

Main Results:

• A 4-gene signature (PIM1, CISH, SOCS2, ID1) significantly correlated with pSTAT5 status in hematologic tumor cell lines.
• Ruxolitinib treatment decreased the expression of these four genes and reduced pSTAT5 levels in pSTAT5-positive models.
• No significant changes in signature gene expression or pSTAT5 levels were observed in pSTAT5-negative cell lines upon ruxolitinib treatment.

Conclusions:

• The developed 4-gene signature can potentially stratify patients with activated JAK-STAT5 signaling for targeted therapies.
• This gene signature serves as a predictor of pharmacodynamic response to JAK inhibitors, such as ruxolitinib.
• The assay aids in identifying patient populations likely to benefit from treatments targeting the JAK-STAT pathway.